CD19 and CD22 targeted prime CAR-T
/ Chongqing Precision Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 26, 2025
A Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL
(clinicaltrials.gov)
- P1/2 | N=40 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2024 ➔ Jul 2027 | Trial primary completion date: Dec 2023 ➔ Dec 2026
Trial completion date • Trial primary completion date • CD22
April 18, 2023
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL
(clinicaltrials.gov)
- P1/2 | N=40 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2023 ➔ Jul 2024 | Trial primary completion date: Jan 2023 ➔ Dec 2023
CAR T-Cell Therapy • Trial completion date • Trial primary completion date • CD19 • CD22 • IL10 • IL6
April 18, 2023
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
(clinicaltrials.gov)
- P1/2 | N=40 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2023 ➔ Jul 2024 | Trial primary completion date: Jan 2023 ➔ Dec 2023
CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD22 • IL10 • IL6
1 to 3
Of
3
Go to page
1